Navigation Links
AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
Date:10/25/2007

with clonogenic growth of human xenograft derived cell lines.

Conclusions

- All three AEZS-112 follow-up candidates were equal to or more efficient

in exerting cytotoxic activity in tumor cell lines and inhibiting

tubulin polymerization than AEZS-112, whereas induction of cell cycle

arrest and apoptosis was slightly improved;

- An interesting difference to the AEZS-112 profile is the inhibition of

topoisomerase I by compounds 2 and 3. Moreover, compound 2 displayed

significant higher potency for topoisomerase II inhibition than

AEZS-112;

- In vitro plasma and liver microsomal stability of the follow-up

candidates are comparable to AEZS-112, thus demonstrating suitability

for in vivo efficacy studies;

- Interference with clonogenic growth of xenograft-derived cells revealed

variability in the response of the different tumor classes to AEZS-112

and compound 1 treatment as a basis for selection of the most

appropriate in vivo efficacy models.

Based on their interesting in vitro profiles, all three follow-up candidates will be subjected to human tumor xenograft in vivo models aimed at selecting an AEZS-112 follow-up candidate for preclinical development.

The poster presentation is available in the Investor section of the Company's website under "Events and Webcasts" at http://www.aeternazentaris.com.

About AEZS-112

AEZS-112 is a novel oral multi-targeted cytotoxic compound with inhibitory effects on tubulin polymerization, topoisomerase II and angiogenesis. In January 2007, the Company initiated a Phase 1 clinical trial for solid tumors and lymphoma; primary endpoints will focus on determining the safety and tolerability of the compound.

AEZS-112 has shown potent in vitro anti-proliferative activity at nanomolar concentrations against human tumor cell lines of diff
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. A Further Step in Understanding Apoptosis Direct Detection of PARP Cleavage
2. OpGen recruits CEO to further gene-mapping business
3. Better collaboration urged to further Wisconsin biotech
4. Johnson Controls jumping further into hybrid-vehicle battery world
5. The let-7 microRNA Family Regulates RAS: Implications for Development and Oncogenesis
6. RNArticles: RNA Amplification Used to Develop a New In Vitro HCMV Assay
7. Rapid Method Development With the BioLogic DuoFlow Chromatography System for the Purification of His-Tagged Proteins
8. A Multiple Mutation Model System as a Test Development and Training Tool for Denaturing Gradient Gel Electrophoresis
9. Development of a Multiplex Bead-Based Assay for Antibody Screening of a Nonhuman Primate Colony on the Bio-Plex System
10. The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System
11. The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015   Tocagen Inc. , a ... from Tocagen,s ongoing investigational studies were presented at ... American Association of Neurological Surgeons (AANS)/Congress of Neurological ... 2015, in Washington, D.C. ... meeting with FDA and continues to advance towards ...
(Date:5/1/2015)... 01, 2015 OncoTAb, Inc., ... spin-out company, announced that Pinku Mukherjee, Ph.D. has received ... Board of Governors’ highest faculty honor. Mukherjee received the ... , for her innovative research and development of cancer ... represents a crowning moment in my scientific career,” said ...
(Date:5/1/2015)... LONDON , May 1, 2015 ... following equities: Genetic Technologies Ltd (NASDAQ: GENE ... Thermo Fisher Scientific Inc. (NYSE: TMO ), ... Inc. (NYSE: PKI ). Free research report ... http://get.Investor-Edge.com/pdf/?c=Genetic%20Technologies&d=01-May-2015&s=GENE . On Thursday, April 30, 2015, the ...
(Date:4/30/2015)... WARREN, N.J. , April 30, 2015  Roka ... company focused on providing advanced testing solutions for the ... financial results for the first quarter of 2015 on ... markets. Roka Bioscience will also host a ... 7, 2015 to discuss its first quarter financial results. ...
Breaking Biology Technology:Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 2Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 5OncoTAb CSO Awarded the University of North Carolina’s O. Max Gardner Award 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 4Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 5Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2
... Benefiting from recent investments in production and enormous demand ... record quarter. The leading developer of topical biotechnology for hair ... over Q1 of 2010. It was the fastest growth since ... "Although Q1 delivered a stellar number — made ...
... Inc. ("Radius") today announced that the company has raised ... $66 million in equity financing and a commitment by ... to a $25 million multi-draw term loan facility. Five ... Capital, Nordic Bioscience ("Nordic"), and Ipsen Pharma SAS ("Ipsen") ...
... protein isolated from beneficial bacteria found in yogurt and ... for inflammatory bowel disorders (IBD), suggests a study led ... Ph.D. The study, published May 23 in the ... protein, called p40, was effective as an intervention in ...
Cached Biology Technology:First-quarter 2011 Sales Reach $2.25M — 126% Growth Over Q1 of 2010 — for Biotech Developer Divine Skin 2First-quarter 2011 Sales Reach $2.25M — 126% Growth Over Q1 of 2010 — for Biotech Developer Divine Skin 3Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study 2Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study 3Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study 4Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study 5Protein from probiotic bacteria may alleviate inflammatory bowel disorders 2Protein from probiotic bacteria may alleviate inflammatory bowel disorders 3
(Date:3/31/2015)... 31, 2015  Elephant Talk Communications Corp. (NYSE MKT: ... of Software Defined Network Architecture (ET Software DNA® 2.0) ... of approximately $20.4 million for the year ended December ... for the year ended December 31, 2013. ... had completed its multi-year transition away from its legacy ...
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has announced ... 2015-2019" report to their offering. The ... at a CAGR of 23.5 percent over the period ... and the growth prospects of the Global Iris Recognition ... size, the report considers the revenue generated from sales ...
(Date:3/23/2015)... March 23, 2015 SoundView Technology Group issues a ... NXTD ) Wocket smart wallet. SoundView was one of the ... their experience with the Wocket in multiple scenarios and outlets. ... Foods and other retailers, making both debit and credit card ... also says, "If the company meets their plans in 2015, ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
... mobile sequences of DNA left over from viruses, called transposons ... the genome, pose a significant threat to the genetic integrity ... elements are believed to comprise as much as 50 percent ... do to an organism,s DNA, an immune-like response has evolved ...
... generate millions of supercharged stem cells, which can then turn ... itself, has been patented at the University of Central Florida. ... holy grail of sorts in the medical world, because they ... of the most challenging diseases in our time, such as ...
... a simple, paper-based test for drug-resistant tuberculosis (TB) is ... chemist, whose project just received a $1.6 million point-of-care ... initiative created by the Bill & Melinda Gates Foundation. ... minds across scientific disciplines to work on solutions that ...
Cached Biology News:Defending the genome 2Defending the genome 3UCF patented on induced pluripotent stem cells, iPS cells 2University of Texas chemist receives major grant to improve detection of drug-resistant tuberculosis 2
...
... HyPer is the first fully genetically encoded ... of intracellular hydrogen peroxide (H2O2), one of ... on the basis of yellow fluorescent protein ... coli protein OxyR (OxyR-RD), HyPer demonstrates submicromolar ...
Alexa Fluor 647 anti-mouse Qa-2...
... cDNA normalization is essential for hunting ... high-throughput approaches, such as EST sequencing ... Evrogen TRIMMER-DIRECT kit is developed for ... sequences and intended for directional cloning. ...
Biology Products: